Aliases & Classifications for Idiopathic Edema

MalaCards integrated aliases for Idiopathic Edema:

Name: Idiopathic Edema 20 70
Idiopathic Orthostatic Edema 20
Fluid Retention Syndrome 20
Idiopathic Cyclic Edema 20
Body Fluid Retention 70
Edema Idiopathic 54
Fluid Retention 54
Cyclical Edema 20

Classifications:



External Ids:

UMLS 70 C0238094 C0268000

Summaries for Idiopathic Edema

GARD : 20 Idiopathic edema is a common cause of fluid retention and swelling (edema) in women. "Idiopathic" means that the cause of this condition is unknown. Idiopathic edema occurs in the absence of heart, kidney, or liver disease. It is often associated with diabetes, obesity, and emotional problems. The edema may develop periodically or it may persist over time. Swelling of the face, hands, and legs can develop rapidly, and affected individuals typically experience significant changes in their weight over the course of a day. Treatment often includes a low sodium and carbohydrate diet as well as cessation of diuretic therapy (if warranted).

MalaCards based summary : Idiopathic Edema, also known as idiopathic orthostatic edema, is related to migraine with or without aura 1 and pre-eclampsia, and has symptoms including edema An important gene associated with Idiopathic Edema is NPPA (Natriuretic Peptide A), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Glucose / Energy Metabolism. The drugs Clobetasol and Rosiglitazone have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and liver, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Idiopathic Edema

Diseases related to Idiopathic Edema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 279)
# Related Disease Score Top Affiliating Genes
1 migraine with or without aura 1 31.2 INS EDN1 ADM ACE
2 pre-eclampsia 30.5 NPPA INS EDN1 ADM ADIPOQ ACE
3 pericardial effusion 30.2 NPPB NPPA ACE
4 mediastinitis 30.1 MPO INS
5 acute mountain sickness 30.0 EDN1 ACE
6 end stage renal disease 29.8 NPPB INS ADIPOQ ACE
7 hereditary angioedema 29.7 MPO ADM ACE
8 portal hypertension 29.7 INS EDN1 ACE
9 heart valve disease 29.5 NR3C2 NPPB NPPA ACE
10 pulmonary edema 29.5 NPPB NPPA EDN1 ACE
11 conn's syndrome 29.5 NR3C2 NPPA ADIPOQ ACE
12 non-alcoholic steatohepatitis 29.4 PPARG PPARA INS ADIPOQ
13 hypokalemia 29.3 NR3C2 INS AQP2 ACE
14 bartter disease 29.2 NR3C2 AQP2 ACE
15 malignant hypertension 29.1 NPPB NPPA EDN1 ADM ACE
16 pulmonary hypertension 29.1 NPPB NPPA EDN1 ADM ACE
17 sleep apnea 28.9 NPPB INS EDN1 ADIPOQ ACE
18 hyperinsulinism 28.9 PPARG PPARA INS EDN1 ADIPOQ
19 hepatorenal syndrome 28.8 NPPA EDN1 AQP2 AQP1 ACE
20 atherosclerosis susceptibility 28.5 PPARG PPARA MPO INS EDN1 ADIPOQ
21 congestive heart failure 28.5 NR3C2 NPPB NPPA INS EDN1 AQP2
22 liver cirrhosis 28.2 PPARG NPPA INS EDN1 AQP2 ADM
23 kidney disease 27.5 PPARG NR3C2 NPPB NPPA INS EDN1
24 chronic kidney disease 27.4 PPARG NR3C2 NPPB NPPA MPO INS
25 heart disease 27.3 PPARG PPARA NR3C2 NPPB NPPA MPO
26 hypertension, essential 26.6 PPARG PPARA NR3C2 NPPB NPPA MPO
27 hepatic veno-occlusive disease 11.2
28 hellp syndrome 11.0
29 vasculogenic impotence 10.3 NPPA ACE
30 multiple cranial nerve palsy 10.3 MPO ACE
31 hypoaldosteronism 10.3 NPPA ACE
32 glossopharyngeal nerve disease 10.3 MPO ACE
33 mononeuritis of upper limb and mononeuritis multiplex 10.3 MPO ACE
34 mononeuritis multiplex 10.3 MPO ACE
35 silent myocardial infarction 10.3 INS ACE
36 alzheimer disease 11 10.3 PPARG PPARA
37 toxic myocarditis 10.3 NPPB ACE
38 inferior myocardial infarction 10.3 NPPB ACE
39 hereditary angioedema with normal c1inh 10.3 MPO ACE
40 generalized atherosclerosis 10.3 INS ACE
41 potter's syndrome 10.3 INS ACE
42 severe nonproliferative diabetic retinopathy 10.3 INS ACE
43 scleral disease 10.3 MPO ACE
44 renal artery disease 10.3 NPPA ACE
45 kidney hypertrophy 10.2 INS ACE
46 conjunctival folliculosis 10.2 MPO ACE
47 first-degree atrioventricular block 10.2 NPPB ACE
48 lateral myocardial infarction 10.2 NR3C2 ACE
49 constrictive pericarditis 10.2 NPPB ACE
50 pure autonomic failure 10.2 NPPA ACE

Graphical network of the top 20 diseases related to Idiopathic Edema:



Diseases related to Idiopathic Edema

Symptoms & Phenotypes for Idiopathic Edema

UMLS symptoms related to Idiopathic Edema:


edema

MGI Mouse Phenotypes related to Idiopathic Edema:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.11 ACE ADIPOQ ADM AQP1 EDN1 INS
2 homeostasis/metabolism MP:0005376 10.03 ACE ADIPOQ ADM AQP1 AQP2 EDN1
3 hematopoietic system MP:0005397 10.02 ACE ADIPOQ ADM AQP1 AQP2 INS
4 mortality/aging MP:0010768 9.9 ACE ADIPOQ ADM AQP1 AQP2 EDN1
5 adipose tissue MP:0005375 9.88 ACE ADIPOQ AQP1 INS PPARA PPARG
6 muscle MP:0005369 9.61 ADIPOQ ADM EDN1 INS MPO NPPA
7 renal/urinary system MP:0005367 9.36 ACE ADIPOQ ADM AQP1 AQP2 EDN1

Drugs & Therapeutics for Idiopathic Edema

Drugs for Idiopathic Edema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 53)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 32798 5311051
2
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
3
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
4
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
5
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
6
Insulin detemir Approved Phase 4 169148-63-4 5311023
7
Zinc Approved, Investigational Phase 4 7440-66-6 32051
8 Sodium Chloride Symporter Inhibitors Phase 4
9 Hypoglycemic Agents Phase 4
10 Diuretics, Potassium Sparing Phase 4
11 Sodium Potassium Chloride Symporter Inhibitors Phase 4
12 Antihypertensive Agents Phase 4
13 insulin Phase 4
14 Insulin, Globin Zinc Phase 4
15 Isophane Insulin, Human Phase 4
16 Isophane insulin, beef Phase 4
17 Insulin, Isophane Phase 4
18
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
19
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
20
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
21
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
22 Hormone Antagonists Phase 3
23 Hormones Phase 3
24 Tubulin Modulators Phase 3
25 Antiemetics Phase 3
26 Gastrointestinal Agents Phase 3
27 Antimitotic Agents Phase 3
28 glucocorticoids Phase 3
29 Antineoplastic Agents, Hormonal Phase 3
30 Anti-Inflammatory Agents Phase 3
31
Pioglitazone Approved, Investigational Phase 2 111025-46-8 4829
32
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
33
2,4-thiazolidinedione Investigational Phase 2 2295-31-0
34 Liver Extracts Phase 2
35 Protein Kinase Inhibitors Phase 2
36
Fentanyl Approved, Illicit, Investigational, Vet_approved 437-38-7 3345
37
Midazolam Approved, Illicit 59467-70-8 4192
38
Sevoflurane Approved, Vet_approved 28523-86-6 5206
39
Rocuronium Approved 119302-91-9, 143558-00-3 441290
40
Propofol Approved, Investigational, Vet_approved 2078-54-8 4943
41
Lidocaine Approved, Vet_approved 137-58-6 3676
42
Norepinephrine Approved 51-41-2 439260
43
Digoxin Approved 20830-75-5 30322 2724385
44
Hydralazine Approved 86-54-4 3637
45 Mineralocorticoid Receptor Antagonists
46 diuretics
47 Mineralocorticoids
48 Anesthetics
49 Anticoagulants
50 Adrenergic beta-Antagonists

Interventional clinical trials:

(show all 17)
# Name Status NCT ID Phase Drugs
1 Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid in Patients With Bullous Pemphigoid Unknown status NCT02360202 Phase 4 Clobetasol Propionate cream treatment
2 A Randomised Study Examining the Effect of Different Diuretics on Fluid Balance in Diabetics Treated With Avandia Completed NCT00306696 Phase 4 Rosiglitazone;spironolactone;hydrochlorothiazide;frusemide
3 Effects of Insulin Detemir and NPH Insulin on Renal Handling of Sodium, Fluid Retention and Weight in Type 2 Diabetic Patients Completed NCT00742976 Phase 4 Insulin Detemir; Insulin Insulatard;Insulin Detemir, Insulin Insulatard
4 A 16-week, Randomised, Double-blind, Placebo-controlled, Single-centre Study to Investigate Fluid Retention in Insulin-treated Subjects With Type 2 Diabetes Mellitus and Varying Degrees of Autonomic Neuropathy When Administered Rosiglitazone 4mg Twice Daily Completed NCT00422955 Phase 3 rosiglitazone
5 A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer Completed NCT01188187 Phase 3 Custirsen;Docetaxel;Prednisone;Dexamethasone
6 Pioglitazone for Lung Cancer Chemoprevention Completed NCT00780234 Phase 2 PIOGLITAZONE VS. PLACEBO 30 mg
7 A Randomized, Phase II Study of Succinylated Gelatin for Prevention of Fluid Retention in Patients With Breast Cancer Receiving Docetaxel Chemotherapy Completed NCT04637308 Phase 2 Succinylated gelatin
8 Phase II Trial of Weekly Docetaxel (Taxotere) Vs. Weekly Docetaxel in Combination With ZD1839 (Iressa®) As Consolidation Therapy For Metastatic Urothelial Cancer Following Maximal Response To Multi-Agent Chemotherapy Terminated NCT00479089 Phase 2 Docetaxel;ZD1839;Dexamethasone
9 Effect of Passive Leg Rasing on Changes in Volumetric Hemodynamic Parameters Induced by Fluid Removal Unknown status NCT02702544
10 Multi-Disciplinary Rehabilitation Program in Recently Hospitalized Patients With Preserved Ejection Fraction Heart Failure Unknown status NCT01914315
11 Measuring Thoracic Impedance in Hemodialysis Patients With the µ-Cor System A Pre-Market Validation Study (MaTcH) Completed NCT03072732
12 Study of Idiopathic Edema Completed NCT01681927
13 A Post-authorization, Observational Study to Assess the Impact of Blue Light Cystoscopy After Administration of Hexaminolevulinate (Hexvix) in the Diagnosis and Treatment of Patients With Non-invasive Bladder Cancer. Completed NCT00634621 Hexaminolevulinate (Hexvix)
14 Comparison of the Effects of Perioperative Liberal and Restrictive Fluid Management on the Endothelial Glycocalyx Layer in Radical Cystectomy and Urinary Diversion Recruiting NCT04780490
15 Swedish Evaluation of Left Ventricular Assist Device Recruiting NCT02592499
16 The Effect of AMP Human Sodium Bicarbonate Lotion on Hydration (AMPlify Human Hydration Study) Not yet recruiting NCT04598386
17 Treatment of Severe Hypertension With Impendence Cardiography (ICG) Directed Therapy; a Randomized Controlled Trial Not yet recruiting NCT04748107

Search NIH Clinical Center for Idiopathic Edema

Genetic Tests for Idiopathic Edema

Anatomical Context for Idiopathic Edema

MalaCards organs/tissues related to Idiopathic Edema:

40
Heart, Kidney, Liver, Pituitary, Myeloid, Endothelial, Testes

Publications for Idiopathic Edema

Articles related to Idiopathic Edema:

(show top 50) (show all 270)
# Title Authors PMID Year
1
Effectiveness of human atrial natriuretic peptide administration in a patient with idiopathic edema. 54 61
10095189 1999
2
Case Report: Clinical Analysis of Seven Neonates With Prader-Willi Syndrome and Review of the Literature. 61
33681108 2021
3
Idiopathic Edema: A Case Report. 61
31572635 2019
4
Acute scrotal idiopathic edema: A misleading erythema. 61
28625172 2018
5
Idiopathic "Cyclic" Edema: A Frustrating and Poorly Understood Clinical Problem. 61
30539703 2018
6
Sleep Apnea and Idiopathic Leg Edema: A Case Control Study. 61
29228525 2017
7
Clinical Characteristics of Overhydration in Patients with Idiopathic Edema. 61
27222015 2016
8
Clinical Features of Neonates with Hydrops Fetalis. 61
26070120 2015
9
The confounding effect of the development of idiopathic orthostatic edema and thyrotoxcosis on weight fluctuation related to effects on free water clearance in a woman with long-standing surgically induced panhypopituitarism and diabetes insipidus. 61
26152015 2015
10
Hyaluronidase injection for the treatment of eyelid edema: a retrospective analysis of 20 patients. 61
24886711 2014
11
Mood-dependent changes of serum lithium concentration in a rapid cycling patient maintained on stable doses of lithium carbonate. 61
23521652 2013
12
[The analysis of selected biochemical parameters concentration in pregnant women with idiopathic edema of the lower limbs--preliminary report]. 61
23342893 2012
13
Non-surgical periodontal therapy improves serum levels of C-reactive protein and edematous states in female patients with idiopathic edema. 61
20681817 2011
14
A case report of systemic capillary leak syndrome (Clarkson's disease). 61
20148770 2010
15
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. 54
20118174 2010
16
Successful treatment of a female with chronic pseudo-intestinal obstruction with sympathomimetic amines and thyroid hormone replacement. 61
21077500 2010
17
Idiopathic edema, a condition associated with pelvic pain and other symptoms in women, as a remedial cause of chronic cold induced urticaria. 61
21077535 2010
18
Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. 54
19906796 2010
19
PPARgamma Agonists: Blood Pressure and Edema. 54
20069049 2010
20
PPARgamma agonists, modulation of ion transporters, and fluid retention. 54
19820124 2009
21
Interleukin-6 and tumor necrosis factor-alpha as biochemical markers of heart failure: a head-to-head clinical comparison with B-type natriuretic peptide. 54
19553828 2009
22
Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes. 54
19545925 2009
23
PPARgamma agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line. 54
19403648 2009
24
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia. 54
19530681 2009
25
PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention. 54
19471887 2009
26
The role of Sgk-1 in the upregulation of transport proteins by PPAR-{gamma} agonists in human proximal tubule cells. 54
18997160 2009
27
Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes. 54
19298680 2009
28
Nesiritide following maze and mitral valve surgery. 54
18928481 2008
29
Beyond the classic angiotensin-receptor-blocker profile. 54
18580862 2008
30
[Obesity and hypertension]. 54
18773751 2008
31
Thiazolidinedione insulin sensitizers and the heart: a tale of two organs? 54
18333890 2008
32
PPAR Agonists and Cardiovascular Disease in Diabetes. 54
18288280 2008
33
Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist farglitazar. 54
18004211 2007
34
Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus. 54
17307062 2007
35
[Development of body weight during antidiabetic treatment]. 54
17139582 2006
36
Relation of body fluid status to B-type natriuretic peptide levels in patients with chronic heart failure during long-term follow-up. 54
17063950 2006
37
The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients. 54
16822823 2006
38
Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes. 54
16882276 2006
39
[Diuretics]. 54
16689377 2006
40
New treatment strategies for patients with hypertension and insulin resistance. 54
16563944 2006
41
Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure. 54
16628020 2006
42
Fluid retention and vascular effects of rosiglitazone in obese, insulin-resistant, nondiabetic subjects. 54
16505510 2006
43
Approach to leg edema of unclear etiology. 61
16513903 2006
44
Thiazolidinediones in patients with diabetes mellitus and heart failure : implications of emerging data. 54
17083264 2006
45
The treatment of idiopathic edema, a cause of chronic pelvic pain in women: effectively controlled chronic refractory urticaria--case reports. 61
17089586 2006
46
Drug treatment of systolic and of diastolic heart failure in elderly persons. 54
16424295 2005
47
PPARgamma agonists do not directly enhance basal or insulin-stimulated Na(+) transport via the epithelial Na(+) channel. 54
16170524 2005
48
Recombinant human growth hormone therapy in HIV-associated wasting and visceral adiposity. 54
16207164 2005
49
Cyclic Cushing's disease with paradoxical response to dexamethasone. 61
16277172 2005
50
Fluid retention mediated by renal PPARgamma. 54
16098822 2005

Variations for Idiopathic Edema

Expression for Idiopathic Edema

Search GEO for disease gene expression data for Idiopathic Edema.

Pathways for Idiopathic Edema

Pathways related to Idiopathic Edema according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.83 PPARG PPARA NPPB NPPA INS ADIPOQ
2 12.22 PPARG INS AQP2 ADIPOQ
3
Show member pathways
12.08 NPPB NPPA EDN1 ADM
4
Show member pathways
11.9 NPPB NPPA EDN1
5
Show member pathways
11.87 PPARG INS ADIPOQ
6 11.67 NPPA INS EDN1
7 11.56 PPARG INS ADIPOQ
8
Show member pathways
11.5 PPARG PPARA NR3C2
9 11.38 PPARG PPARA INS ADIPOQ
10 11.31 PPARG PPARA ADIPOQ
11 10.93 PPARG ADIPOQ
12 10.84 PPARG ADIPOQ
13 10.82 NPPB NPPA
14 10.76 NPPA EDN1 AQP1 ACE

GO Terms for Idiopathic Edema

Cellular components related to Idiopathic Edema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 NPPB NPPA MPO INS IL11 EDN1
2 extracellular space GO:0005615 9.28 NPPB NPPA MPO INS IL11 EDN1

Biological processes related to Idiopathic Edema according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.19 PPARG NR3C2 NPPA INS IL11 ADM
2 negative regulation of inflammatory response GO:0050728 9.84 PPARG PPARA ADIPOQ
3 heart development GO:0007507 9.84 PPARG PPARA EDN1 ADM
4 negative regulation of cell growth GO:0030308 9.81 PPARG NPPB NPPA
5 glucose homeostasis GO:0042593 9.8 PPARG INS ADIPOQ
6 transcription initiation from RNA polymerase II promoter GO:0006367 9.8 PPARG PPARA NR3C2 NPPA
7 response to insulin GO:0032868 9.75 PPARA NPPA ADM
8 regulation of blood vessel diameter GO:0097746 9.68 NPPB ACE
9 regulation of vasoconstriction GO:0019229 9.67 EDN1 ACE
10 positive regulation of blood vessel diameter GO:0097755 9.67 INS ADM
11 negative regulation of reactive oxygen species biosynthetic process GO:1903427 9.66 PPARA INS
12 positive regulation of lipid biosynthetic process GO:0046889 9.66 PPARA INS
13 negative regulation of gluconeogenesis GO:0045721 9.65 INS ADIPOQ
14 response to lipid GO:0033993 9.65 PPARG PPARA
15 water transport GO:0006833 9.65 AQP2 AQP1
16 response to hypoxia GO:0001666 9.65 PPARA NPPA EDN1 ADM ADIPOQ
17 response to muscle stretch GO:0035994 9.63 NPPA EDN1
18 fatty acid oxidation GO:0019395 9.63 PPARG ADIPOQ
19 positive regulation of renal sodium excretion GO:0035815 9.62 NPPB EDN1
20 positive regulation of urine volume GO:0035810 9.61 NPPB EDN1
21 negative regulation of systemic arterial blood pressure GO:0003085 9.61 NPPB NPPA
22 cGMP biosynthetic process GO:0006182 9.6 NPPB NPPA
23 negative regulation of cholesterol storage GO:0010887 9.59 PPARG PPARA
24 receptor guanylyl cyclase signaling pathway GO:0007168 9.58 NPPB NPPA
25 positive regulation of heart rate GO:0010460 9.58 NPPA EDN1 ADM
26 glycerol transport GO:0015793 9.57 AQP2 AQP1
27 body fluid secretion GO:0007589 9.56 NPPB EDN1
28 negative regulation of acute inflammatory response GO:0002674 9.55 PPARG INS
29 cGMP-mediated signaling GO:0019934 9.54 NPPB NPPA AQP1
30 positive regulation of fatty acid oxidation GO:0046321 9.52 PPARG PPARA
31 negative regulation of sequestering of triglyceride GO:0010891 9.51 PPARG PPARA
32 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.5 PPARG PPARA ADIPOQ
33 cellular response to mercury ion GO:0071288 9.48 AQP2 AQP1
34 nitric oxide transport GO:0030185 9.46 EDN1 AQP1
35 renal water transport GO:0003097 9.43 AQP2 AQP1
36 negative regulation of hormone secretion GO:0046888 9.33 IL11 EDN1 ADIPOQ
37 positive regulation of fatty acid metabolic process GO:0045923 9.13 PPARG PPARA ADIPOQ
38 regulation of blood pressure GO:0008217 9.02 PPARG NPPB NPPA EDN1 ACE

Molecular functions related to Idiopathic Edema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.55 NPPB NPPA EDN1 ADM ADIPOQ
2 steroid hormone receptor activity GO:0003707 9.43 PPARA NR3C2
3 nuclear receptor activity GO:0004879 9.43 PPARG PPARA NR3C2
4 water channel activity GO:0015250 9.4 AQP2 AQP1
5 hormone receptor binding GO:0051427 9.37 NPPB NPPA
6 water transmembrane transporter activity GO:0005372 9.32 AQP2 AQP1
7 hormone activity GO:0005179 9.1 NPPB NPPA INS EDN1 ADM ADIPOQ
8 glycerol transmembrane transporter activity GO:0015168 8.96 AQP2 AQP1

Sources for Idiopathic Edema

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....